Abbott On Track To Reach U.S. Drug-Eluting Stent Market By Late 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Company earns FDA green light for planned 1,670-patient ZOMAXX II randomized trial of ZoMaxx drug-eluting stent. Study will compare ABT-578-eluting TriMaxx-platform stent to Boston Scientific's Taxus.